Market Overview:
The global Glucose Dependent Insulinotropic Receptor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of type 2 diabetes, obesity, and chronic obstructive pulmonary disease (COPD) across the globe. Additionally, rising awareness about dyslipidemia and its treatment is also contributing to the growth of this market. On the basis of type, DA-1241 is expected to be one of the most promising segments in this market during the forecast period. This segment is projected to grow at a CAGR of XX%. HD-0471042 and HD-0471953 are other key types that are expected to witness high demand during the forecast period. On account on application, type 2 diabetes currently dominates this market and is anticipated hold its dominant position over other applications such as obesity, COPD dyslipidemia etc.
Product Definition:
A receptor that is activated by insulin and other hormones to stimulate the production of insulin from pancreatic beta cells.
DA-1241:
DA-1241 is a prescription drug, which has been developed by the Daewoong Pharmaceutical Co., Ltd. in South Korea. It is an oral spray that contains dextrose and insulin in equal parts along with the active ingredient, known as 11b-hydroxyetioic acid or 11-BHETIA for short.
GSK-2041706:
GSK-2041706 (ZDDP) is a highaffinity zinc binding domain protein. It has been studied in combination with glucagon like peptide and used as an insulin sensitizer for the treatment of type II diabetes. GSK- 2041706 is under clinical investigation for treating type II diabetes and obesity.
Application Insights:
The application segment includes type 2 diabetes, obesity, chronic obstructive pulmonary disease (COPD), dyslipidemia and others. Type 2 diabetes dominated the global market in terms of revenue in 2017. The increasing prevalence of this condition is anticipated to drive the segment over the forecast period. According to WHO, more than 400 million people are suffering from type 2 diabetes worldwide while approximately 90 million people were diagnosed with this condition in 2015 globally.
The growing prevalence of obesity coupled with limited treatment options available for managing this health issue is expected to boost demand for new glucose-dependent insulinotropic receptors over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, availability of advanced technologies and high prevalence of diabetes are some factors attributing to its largest share. In addition, increasing government funding for research activities is also expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as China & India. Furthermore, an increase in diabetic patients due to sedentary lifestyle and poor dietary habits will boost product demand during the estimated time span.
Growth Factors:
- Rising prevalence of diabetes: The global prevalence of diabetes is rising at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increasing demand for therapies that can help manage blood sugar levels effectively. Glucose dependent insulinotropic receptor (GDIR) agonists are one such class of drugs that have been shown to be effective in managing blood sugar levels in patients with diabetes mellitus type 2.
- Growing awareness about GDIR therapy: There is growing awareness among healthcare professionals and patients about the benefits of GDIR therapy for managing blood sugar levels in patients with diabetes mellitus type 2. This is likely to lead to an increase in demand for GDIR agonists over the next few years.
- Availability of novel GDIR agonists: A number of novel GDIR agonists are currently under development and are expected to be launched in the market over the next few years. These new drugs are likely to boost growth prospects for the glucose dependent insulinotropic receptor market as they offer better efficacy and safety profiles than existing therapies available in this space..
- . This is likely to lead to increased competition within this market, which will ultimately benefit consumers through innovation and introduction
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucose Dependent Insulinotropic Receptor Market Research Report
By Type
DA-1241, GSK-2041706, HD-0471042, HD-0471953, HOB-047, MBX-2982, Others
By Application
Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease (COPD), Dyslipidemia, Others
By Companies
Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd, Merck & Co Inc, Novartis AG, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Yuhan Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Glucose Dependent Insulinotropic Receptor Market Report Segments:
The global Glucose Dependent Insulinotropic Receptor market is segmented on the basis of:
Types
DA-1241, GSK-2041706, HD-0471042, HD-0471953, HOB-047, MBX-2982, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease (COPD), Dyslipidemia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc
- Arena Pharmaceuticals Inc
- CymaBay Therapeutics Inc
- Dong-A Socio Holdings Co Ltd
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Hyundai Pharmaceutical Co Ltd
- Kowa Co Ltd
- Merck & Co Inc
- Novartis AG
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Co Ltd
- Yuhan Corp
Highlights of The Glucose Dependent Insulinotropic Receptor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DA-1241
- GSK-2041706
- HD-0471042
- HD-0471953
- HOB-047
- MBX-2982
- Others
- By Application:
- Type 2 Diabetes
- Obesity
- Chronic Obstructive Pulmonary Disease (COPD)
- Dyslipidemia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucose Dependent Insulinotropic Receptor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glucose Dependent Insulinotropic Receptor (GIRK) is a protein that helps control blood sugar levels. When glucose levels are high, GIRK signals the body to release insulin. Insulin helps to move glucose from the blood into cells where it can be used for energy.
Some of the key players operating in the glucose dependent insulinotropic receptor market are Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd, Merck & Co Inc, Novartis AG, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Yuhan Corp.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glucose Dependent Insulinotropic Receptor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glucose Dependent Insulinotropic Receptor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glucose Dependent Insulinotropic Receptor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glucose Dependent Insulinotropic Receptor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glucose Dependent Insulinotropic Receptor Market Size & Forecast, 2020-2028
4.5.1 Glucose Dependent Insulinotropic Receptor Market Size and Y-o-Y Growth
4.5.2 Glucose Dependent Insulinotropic Receptor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 DA-1241
5.2.2 GSK-2041706
5.2.3 HD-0471042
5.2.4 HD-0471953
5.2.5 HOB-047
5.2.6 MBX-2982
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Type 2 Diabetes
6.2.2 Obesity
6.2.3 Chronic Obstructive Pulmonary Disease (COPD)
6.2.4 Dyslipidemia
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glucose Dependent Insulinotropic Receptor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glucose Dependent Insulinotropic Receptor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 DA-1241
9.6.2 GSK-2041706
9.6.3 HD-0471042
9.6.4 HD-0471953
9.6.5 HOB-047
9.6.6 MBX-2982
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Type 2 Diabetes
9.10.2 Obesity
9.10.3 Chronic Obstructive Pulmonary Disease (COPD)
9.10.4 Dyslipidemia
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 DA-1241
10.6.2 GSK-2041706
10.6.3 HD-0471042
10.6.4 HD-0471953
10.6.5 HOB-047
10.6.6 MBX-2982
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Type 2 Diabetes
10.10.2 Obesity
10.10.3 Chronic Obstructive Pulmonary Disease (COPD)
10.10.4 Dyslipidemia
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 DA-1241
11.6.2 GSK-2041706
11.6.3 HD-0471042
11.6.4 HD-0471953
11.6.5 HOB-047
11.6.6 MBX-2982
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Type 2 Diabetes
11.10.2 Obesity
11.10.3 Chronic Obstructive Pulmonary Disease (COPD)
11.10.4 Dyslipidemia
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 DA-1241
12.6.2 GSK-2041706
12.6.3 HD-0471042
12.6.4 HD-0471953
12.6.5 HOB-047
12.6.6 MBX-2982
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Type 2 Diabetes
12.10.2 Obesity
12.10.3 Chronic Obstructive Pulmonary Disease (COPD)
12.10.4 Dyslipidemia
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 DA-1241
13.6.2 GSK-2041706
13.6.3 HD-0471042
13.6.4 HD-0471953
13.6.5 HOB-047
13.6.6 MBX-2982
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Type 2 Diabetes
13.10.2 Obesity
13.10.3 Chronic Obstructive Pulmonary Disease (COPD)
13.10.4 Dyslipidemia
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glucose Dependent Insulinotropic Receptor Market: Competitive Dashboard
14.2 Global Glucose Dependent Insulinotropic Receptor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc
14.3.2 Arena Pharmaceuticals Inc
14.3.3 CymaBay Therapeutics Inc
14.3.4 Dong-A Socio Holdings Co Ltd
14.3.5 F. Hoffmann-La Roche Ltd
14.3.6 GlaxoSmithKline Plc
14.3.7 Hyundai Pharmaceutical Co Ltd
14.3.8 Kowa Co Ltd
14.3.9 Merck & Co Inc
14.3.10 Novartis AG
14.3.11 Taisho Pharmaceutical Holdings Co Ltd
14.3.12 Takeda Pharmaceutical Co Ltd
14.3.13 Yuhan Corp
